Products
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Vitamin B12 test kit

SNX-2112 (PF-04928473)

Cat. No.: OB0225WX-2506
Appearance: Solid
Purity: ≥99%
Identity: Confirmed by NMR, and HPLC.
Size:
SNX-2112 (PF-04928473)
Add to basket

Product Overview

Description: SNX-2112 (PF-04928473) is a selective ligand that binds to the ATP-binding pocket of both HSP90-alpha and HSP90-beta with a binding affinity (Ka) of 30 nM.
Synonym: 908112-43-6; SNX-2112; 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide; PF-04928473; 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide; 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-(((1r,4r)-4-hydroxycyclohexyl)amino)benzamide; 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(cis-4-hydroxycyclohexyl)amino]benzamide; Benzamide, 2-((trans-4-hydroxycyclohexyl)amino)-4-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl)-; 4-(6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((trans-4-hydroxycyclohexyl)amino)benzamide; 4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(trans-4-hydroxy-cyclohexylamino)-benzamide; 4-[6,6-dimethyl-4-oxidanylidene-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-oxidanylcyclohexyl)amino]benzamide; 4-(6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-(trans-4-hydroxycyclohexylamino)benzamide; 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1h-indazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide
CAS No.: 908112-43-6
Compound CID: 24772860
Formula: C23H27F3N4O3
Formula Weight: 464.48

Specification

Stability: 3 years in powder form.
Storage: Storage at -20°C.
Applications: SNX-2112 (PF-04928473) is applied in proteostasis research as a potent Hsp90 inhibitor to study the degradation of oncogenic client proteins and the modulation of the cellular stress response.

Library Information

Target: HSP (HSP90)
Receptor: HSP90α; HSP90β
Pathways: Cytoskeletal signaling
Plate Number: L6700-04
Empty Location: a1-h1; a12-h12
Container: 96-well plate
Formulation: 10mM DMSO
DMSO Max Solubility: 93 mg/mL; 200.22 mM
Ethanol Max Solubility: 1 mg/mL
ALogP: 3.709
HBA_Count: 3
HBD_Count: 3
Rotatable Bond: 5
Inquiry
0
Inquiry Basket

Copyright © Protheragen. All rights reserves.